AJR Am J Roentgenol

1. FERRAIOLI G, Roccarina D, Barr RG
   Attenuation Coefficient for Hepatic Steatosis Using a Single Ultrasound System: Associations of Measurement Parameters With Interoperator Agreement and Diagnostic Performance.
   AJR Am J Roentgenol. 2025 Apr 16. doi: 10.2214/AJR.25.32746.
   

   >> Share

   
   
2. HONG CW, Yang Y, Remick I, Su P, et al
   Flip Angle Optimization for Hepatobiliary Phase MRI at 0.55 T in Patients With Metastatic Neuroendocrine Tumors: A Prospective Study.
   AJR Am J Roentgenol. 2025 Apr 16. doi: 10.2214/AJR.25.32888.
   

   >> Share

   
   

   
   Biochem Biophys Res Commun

3. KUDO J, Hirono H, Ohkoshi S
   Low-frequency, mild-gradient chronic intermittent hypoxia still induces liver fibrogenesis in mice on a high-fat diet.
   Biochem Biophys Res Commun. 2025;761:151744.
   

   >> Share

   
   

   
   BMC Cancer

4. LIN Y, Ma Y, Chen Y, Huang Y, et al
   Diagnostic and prognostic performance of serum GPC3 and PIVKA-II in AFP-negative hepatocellular carcinoma and establishment of nomogram prediction models.
   BMC Cancer. 2025;25:721.
   

   >> Share

   
   
5. XUE JS, Maimaitiming N, Zhang BL, Xu BW, et al
   Prognostic analysis of patients with CRLM based on CRS score: a single-center retrospective study.
   BMC Cancer. 2025;25:718.
   

   >> Share

   
   
6. YANG J, Xu Q, Luo S, Wu J, et al
   Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study.
   BMC Cancer. 2025;25:708.
   

   >> Share

   
   
7. GUO X, Song J, Zhu L, Liu S, et al
   Multiparametric MRI-based radiomics and clinical nomogram predicts the recurrence of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization.
   BMC Cancer. 2025;25:683.
   

   >> Share

   
   

   
   BMC Gastroenterol

8. RABIU NM, Muhammad AR, Umar AB, Donzomga SD, et al
   "Evaluation of hepatobiliary disorders using magnetic resonance cholangiopancreatography in a low-resource setting in Kano, Nigeria: a retrospective study".
   BMC Gastroenterol. 2025;25:254.
   

   >> Share

   
   
9. ZHOU Y, Lin H, Weng X, Dai H, et al
   Correlation between hs-CRP-triglyceride glucose index and NAFLD and liver fibrosis.
   BMC Gastroenterol. 2025;25:252.
   

   >> Share

   
   
10. HUANG L, Luo Y, Zhang L, Wu M, et al
    Machine learning-based disease risk stratification and prediction of metabolic dysfunction-associated fatty liver disease using vibration-controlled transient elastography: Result from NHANES 2021-2023.
    BMC Gastroenterol. 2025;25:255.
    

    >> Share

    
    
11. LIU S, Zhou M, Chen P, Deng X, et al
    A nomogram for prognostic prediction and for therapeutic decision making of elderly HCC patients.
    BMC Gastroenterol. 2025;25:257.
    

    >> Share

    
    
12. ARASTEH B, Hamzehzadeh S, Toutounchi KS, Nikniaz Z, et al
    Association of ultrasound signs of sarcopenia with serum ferritin levels and hepatic indices like NFS and FIB-4 in NAFLD patients.
    BMC Gastroenterol. 2025;25:261.
    

    >> Share

    
    
13. KAMANI L, Siddiqui M, Rahat A
    Frequency of insulin resistance among non-diabetic patients with non-alcoholic fatty liver disease using HOMA-IR: an experience of a tertiary care hospital in Karachi, Pakistan.
    BMC Gastroenterol. 2025;25:259.
    

    >> Share

    
    
14. HOSSEINI MS, Barjesteh F, Azedi F, Alipourfard I, et al
    Comparative analysis of beta-Estradiol and testosterone on lipid droplet accumulation, and regulatory protein expression in palmitate/oleate-induced fatty HepG2 cells.
    BMC Gastroenterol. 2025;25:263.
    

    >> Share

    
    
15. FENG X, Song X, Yang X, Luan F, et al
    MAFLD mediates the association between CHR and gallstones in the U.S. adults: evidence from NHANES 2021-2023.
    BMC Gastroenterol. 2025;25:268.
    

    >> Share

    
    
16. GUO Y, Su W, Tao L, Zhang G, et al
    The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study.
    BMC Gastroenterol. 2025;25:265.
    

    >> Share

    
    
17. WU F, Zheng F, Li X, Wu D, et al
    Association between non-skimmed milk consumption and metabolic dysfunction-associated fatty liver disease in US adults: insights from NHANES data.
    BMC Gastroenterol. 2025;25:270.
    

    >> Share

    
    
18. MOON SY, Son M, Kang YW, Koh M, et al
    Associations between non-insulin-based insulin resistance surrogate markers and liver-related outcomes in metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study in South Korea.
    BMC Gastroenterol. 2025;25:274.
    

    >> Share

    
    

    
    Br J Surg

19. NING J, Dai C, Liu Q, Lin H, et al
    Application of the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) technique in conversion therapy for hepatocellular carcinoma.
    Br J Surg. 2025;112:znaf067.
    

    >> Share

    
    

    
    Dig Dis Sci

20. YANG W, Li D, Zhang J
    Transcatheter Arterial Chemoembolization in a Patient with Complete Situs Inversus Totalis and Massive Primary Hepatocellular Carcinoma.
    Dig Dis Sci. 2025 Apr 16. doi: 10.1007/s10620-025-09035.
    

    >> Share

    
    

    
    Endoscopy

21. NI J, Li F, Peng K, Mao Y, et al
    Hybrid endoscopic approach for recanalization of biliary-enteric anastomotic occlusion with impacted hepatic stones in Roux-en-Y reconstruction.
    Endoscopy. 2025;57.
    

    >> Share

    
    

    
    Eur Radiol

22. MU M, Cao Y, Chen Z, Fu X, et al
    Inferior vena cava-splenic vein shunt for the treatment of complete portal trunk occlusion and portal cavernoma in liver cirrhosis.
    Eur Radiol. 2025 Apr 17. doi: 10.1007/s00330-025-11571.
    

    >> Share

    
    
23. ZHANG Y, Zhang Z, Yin X, Xu A, et al
    Hepatic arterial infusion chemotherapy versus transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.
    Eur Radiol. 2025 Apr 11. doi: 10.1007/s00330-025-11557.
    

    >> Share

    
    

    
    Gastroenterology

24. YOUNOSSI ZM, Zelber-Sagi S, Lazarus JV, Wai-Sun Wong V, et al
    Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis.
    Gastroenterology. 2025 Apr 11:S0016-5085(25)00632.
    

    >> Share

    
    

    
    Hepatology

25. YU Y, You Y, Duan Y, Kang M, et al
    Multiomics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001352.
    

    >> Share

    
    
26. HOLMER M, Ingre M, Farkkila M, Ponsioen C, et al
    Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.
    Hepatology. 2025 Apr 16. doi: 10.1097/HEP.0000000000001351.
    

    >> Share

    
    
27. NORDEN-KRICHMAR TM, Rotroff D, Schwantes-An TH, Bataller R, et al
    Genomic approaches to explore susceptibility and pathogenesis of alcohol use disorder and alcohol-associated liver disease.
    Hepatology. 2025;81:1595-1606.
    

    >> Share

    
    
28. DE RUDDER M, Manco R, Coubeau L, Fontaine A, et al
    Vascular damage and excessive proliferation compromise liver function after extended hepatectomy in mice.
    Hepatology. 2025;81:1468-1484.
    

    >> Share

    
    
29. NOVOA E, da Silva Lima N, Gonzalez-Rellan MJ, Chantada-Vazquez MDP, et al
    Mitochondrial antiviral signaling protein enhances MASLD progression through the ERK/TNFalpha/NFkappabeta pathway.
    Hepatology. 2025;81:1535-1552.
    

    >> Share

    
    
30. MONIAUX N, Geoffre N, Deshayes A, Dos Santos A, et al
    Tumor suppressive role of the antimicrobial lectin REG3A targeting the O -GlcNAc glycosylation pathway.
    Hepatology. 2025;81:1416-1432.
    

    >> Share

    
    
31. OLUBAMIWA AO, Liao TJ, Zhao J, Dehanne P, et al
    Drug interaction with UDP-Glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injury.
    Hepatology. 2025;81:1512-1521.
    

    >> Share

    
    
32. HUANG DQ, Wilson LA, Behling C, Amangurbanova M, et al
    Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study.
    Hepatology. 2025;81:1553-1563.
    

    >> Share

    
    
33. ZHANG S, Yan Y, Zeng XF, Gu Y, et al
    Associations of the EAT-Lancet reference diet with metabolic dysfunction-associated steatotic liver disease and its severity: A multicohort study.
    Hepatology. 2025;81:1583-1594.
    

    >> Share

    
    
34. SUN Y, Wei H, Yu W, Gao H, et al
    The actin-binding protein drebrin disrupts NF2-LATS kinases complex assembly to facilitate liver tumorigenesis.
    Hepatology. 2025;81:1433-1451.
    

    >> Share

    
    
35. YANG Z, Jiang Y, Ma J, Wang L, et al
    LncRNA H19 promoted alcohol-associated liver disease through dysregulation of alternative splicing and methionine metabolism.
    Hepatology. 2025;81:1485-1500.
    

    >> Share

    
    

    
    J Hepatol

36. SUN SS, Zhang J, Jin YP, Li L, et al
    A Rare Cause of Lipid Metabolism Disorder and Cirrhosis in an Adult.
    J Hepatol. 2025 Apr 9:S0168-8278(25)00227-2. doi: 10.1016/j.jhep.2025.
    

    >> Share

    
    
37. ALI K, Al Snih GM, Beyder A, Abdelmalek MF, et al
    Peppermint Oil Associated Hepatotoxicity.
    J Hepatol. 2025 Apr 9:S0168-8278(25)00230-2. doi: 10.1016/j.jhep.2025.
    

    >> Share

    
    
38. NAIK I, Yeo YH, Ng WH, Sheng-Kai Ma K, et al
    Carvedilol is Associated with Lower Risk of Hepatic Decompensation Compared to Other Non-Selective Beta-Blockers in Cirrhosis.
    J Hepatol. 2025 Apr 11:S0168-8278(25)00232-6. doi: 10.1016/j.jhep.2025.
    

    >> Share

    
    
39. TONON M, Gagliardi R, Pompili E, Barone A, et al
    Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease.
    J Hepatol. 2025 Apr 12:S0168-8278(25)00245-4. doi: 10.1016/j.jhep.2025.
    

    >> Share

    
    
40. FERNANDES FF, Ferreira da Silva PG, Villela Nogueira CA
    Follow-up NIT values rather than their variation predict hepatocellular carcinoma after HCV eradication.
    J Hepatol. 2025 Apr 12:S0168-8278(25)00237-5. doi: 10.1016/j.jhep.2025.
    

    >> Share

    
    
41. VITHAYATHIL M, Koku D, Campani C, Nault JC, et al
    Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma.
    J Hepatol. 2025 Apr 15:S0168-8278(25)00244-2. doi: 10.1016/j.jhep.2025.
    

    >> Share

    
    
42. REIBERGER T, Maasoumy B
    Advancing our understanding of recompensated cirrhosis - the new "holy grail" of decompensated cirrhosis.
    J Hepatol. 2025 Apr 16:S0168-8278(25)00241-7. doi: 10.1016/j.jhep.2025.
    

    >> Share

    
    
43. ANGELI P, Labenz C, Piano S, Juanola A, et al
    Albumin infusion in Hepatorenal Syndrome-Acute Kidney Injury: new evidence challenges recent consensus.
    J Hepatol. 2025 Apr 16:S0168-8278(25)00238-7. doi: 10.1016/j.jhep.2025.
    

    >> Share

    
    
44. TAN EY, Danpanichkul P, Yong JN, Yu Z, et al
    Liver cancer in 2021: Global Burden of Disease study.
    J Hepatol. 2025;82:851-860.
    

    >> Share

    
    
45. ABDURRACHIM D, Lek S, Ong CZL, Wong CK, et al
    Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.
    J Hepatol. 2025;82:898-908.
    

    >> Share

    
    
46. CALES P, Canivet CM, Costentin C, Lannes A, et al
    A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD.
    J Hepatol. 2025;82:794-804.
    

    >> Share

    
    
47. CASTOLDI M, Roy S, Angendohr C, Pellegrino R, et al
    Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma.
    J Hepatol. 2025;82:499-511.
    

    >> Share

    
    

    
    J Pediatr Surg

48. BRITS E, Brown S, Botes L, Sempa JB, et al
    Aspartate Aminotransferase-to-platelet Ratio Index (APRi) as Biomarker for Liver Damage in Biliary Atresia (BA): A Meta-analysis.
    J Pediatr Surg. 2025;60:162234.
    

    >> Share

    
    

    
    N Engl J Med

49. RASKO JEJ, Samelson-Jones BJ, George LA, Giermasz A, et al
    Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study.
    N Engl J Med. 2025;392:1508-1517.
    

    >> Share

    
    

    
    Oncogene

50. SHA N, Zhou B, Hou G, Xi Z, et al
    The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation.
    Oncogene. 2025;44:1078-1092.
    

    >> Share

    
    

    
    PLoS One

51. HUANG Y, Ao T, Wang Y, Zhen P, et al
    The red blood cell distribution width is associated with all-cause and cardiovascular mortality among individuals with non-alcoholic fatty liver disease.
    PLoS One. 2025;20:e0321789.
    

    >> Share

    
    
52. WANG Q, Chen R, Chen S, Wei B, et al
    Exploring the association between dietary indices and metabolic dysfunction-associated steatotic liver disease: Mediation analysis and evidence from NHANES.
    PLoS One. 2025;20:e0321251.
    

    >> Share

    
    
53. POMEJ K, Frick A, Scheiner B, Balcar L, et al
    Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot study.
    PLoS One. 2025;20:e0321189.
    

    >> Share

    
    

    
    Semin Liver Dis

54. JIAO H, Wang H, Li J, Yang Z, et al
    The Molecular Pathogenesis of Sarcopenia/Frailty in Cirrhosis.
    Semin Liver Dis. 2025 Apr 16. doi: 10.1055/a-2564-7551.
    

    >> Share

    
    

    
    Transplant Proc

55. FU S, Pan JH, Kadri H, Contag C, et al
    Perioperative Outcomes of Limited Sobriety Versus Standard Sobriety Liver Transplantation for Alcohol-associated Liver Disease.
    Transplant Proc. 2025 Mar 19:S0041-1345(25)00138.
    

    >> Share

    
    
56. OCAK I, Colak M, Bilici BN
    Comparative Analysis of Plasmapheresis Versus Plasmapheresis Combined With Continuous Renal Replacement Therapy in Adult Liver Failure: A Retrospective Observational Study.
    Transplant Proc. 2025 Mar 17:S0041-1345(25)00140.
    

    >> Share

    
    

    
    Transplantation

57. HONG G, Han DK, Rhu J, Hong SK, et al
    Safety and Therapeutic Outcomes of Adjuvant Immunotherapy With Autologous Cytokine-induced Killer Cells for Patients With Hepatocellular Carcinoma Beyond Milan Criteria After Liver Transplantation.
    Transplantation. 2025 Apr 16. doi: 10.1097/TP.0000000000005406.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share